Related Experiment Video

Updated: Jul 16, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment

Alessandro Gozzetti, Monica Bocchia, Simona Calabrese

    Acta Haematologica
    |February 20, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
    10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
    12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
    10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
    12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro.

    European journal of immunology·2026

    Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.

    Apoptosis : an international journal on programmed cell death·2026

    Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

    Blood·2026

    Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

    Blood cancer journal·2026

    MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.

    British journal of haematology·2026

    Left Atrial Strain Correlation with Functional Capacity and Additional Prognostic Value of Speckle Tracking in Cardiac Amyloidosis: A Prospective, Single-Center Study.

    Journal of clinical medicine·2026

    Lactoferrin as a Natural Modulator of Immunity and Iron Homeostasis: A Review of Current Knowledge.

    Acta haematologica·2026

    Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia.

    Acta haematologica·2026

    Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.

    Acta haematologica·2026

    Navigating the Immune Landscape: Balancing Efficacy and Toxicity of BCMA-Targeting Agents in Multiple Myeloma.

    Acta haematologica·2026

    Global Disparities in Multiple Myeloma Quality-of-Care Indicators and Their Association with Socioeconomic Development and Behavioral Risk Factors: An Analysis of GBD 2021 Data.

    Acta haematologica·2026

    Post-Marketing Safety of the Menin Inhibitor Revumenib: A Bayesian Disproportionality Analysis of a National Database.

    Acta haematologica·2026

    High-Intensity 1064 nm Laser Therapy for Temporomandibular Joint Pain: A Prospective Multicenter Study of TriHIL™ Technology.

    Cureus·2026

    Methodical design, development, and evaluation of transferosomal transdermal films for enhanced delivery of lornoxicam and thiocolchicoside.

    Therapeutic delivery·2026

    Recent advances in antituberculosis drugs and therapeutics: from mechanistic breakthroughs to clinical translation.

    Molecular biomedicine·2026

    [Interventional cardiology in 2035: Towards a precision medicine].

    Annales de cardiologie et d'angeiologie·2026

    161Tb Radiopharmaceutical Therapy as a Treatment for RANKL-Positive Multiple Myeloma.

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026

    Sterility testing in the era of decentralised cell therapy: Challenges, innovations, and future directions.

    Biologicals : journal of the International Association of Biological Standardization·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us